Effect of baicalein on experimental prostatic hyperplasia in rats and mice

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 3, 2004, Pages 333-337

  Guo, Qing Long ^a   Ding, Qi Long ^a   Wu, Zhao Qiu ^a,b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Animal model; Baicalein; Prostatic hyperplasia; Scutellaria baicalensis; Testosterone propionate

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AGENTS ACTING ON THE GENITAL SYSTEM; BAICALEIN; DNA; FINASTERIDE; QIAN LEI KANG; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; ACID PHOSPHATASE; FLAVANONE DERIVATIVE;

ACID PHOSPHATASE BLOOD LEVEL; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA CONTENT; DRUG EFFICACY; DRY WEIGHT; ENZYME ACTIVITY; FETUS; HEIGHT; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; ORGAN SIZE; ORGAN WEIGHT; PROSTATE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RAT; UROGENITAL SINUS; ANIMAL; BLOOD; CELL DIVISION; CHEMICAL PHENOMENA; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACID PHOSPHATASE; ANIMALS; CASTRATION; CELL DIVISION; DEPRESSION, CHEMICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; MALE; MICE; ORGAN SIZE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE PROPIONATE;

EID: 16544391656     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.333     Document Type: Article

References (15)

1. Hou Y. L., Zhu X. Y., Cheng G. F., Chinese J. Pharmaceutics, 35, 161-164 (2000).
2. Gao Z. X., Huang K. X., Xu H. B., Chinese J. Pharmaceutics, 33, 505-508 (1998).
3. Zhou R. Z., Gu G. Y., Chinese Traditional Patent Medicine, 131, 28-29 (1991).
4. Bi Y. H., Chinese J. Lintermediate Medical, 338, 53-54 (1998).
5. Zhu Y., Chinese J. Integrated Traditional and Western Medicine, 13, 567-569 (1993).
6. Cai D. X., Mu W. T., Wang L. X., J. Nanjing Railway Medical College, 13, 65-68 (1994).
7. Xu G., Zhang L. P., J. Shanghai Medical University, 20, 187-191 (1993).
8. He Y. G., Shanghai J. Traditional Chinese Medicine, 1, 24-28 (1956).
9. Yuan F. F., Chen S. H., Luo P. P., Wang W. B., Zhu J. G., Lishizhen Chinese Traditional Medicine and Materia Medica, 11, 577-578 (2000).
10. Qian B. C., Liu X. L., Zhang X. X., Qi B. F., Li L. M., Chinese J. Urology, 13, 365-368 (1992).
11. Li F., Cai H. M., Chinese J. Progress in Pharmaceutics, 19, 193-197 (1995).
12. Wu Z. J., Meng X. Q., Guo M. F., Yang X. P., Wang Y. L., J. Hebei Medical University, 19, 156-159 (1998).
13. Xu S. K., "Pharmacology of Anti-senility, Part 3," Vol. I, Chap. 4, ed. by He X. Z., Zhang B. W., Chinese Medical Science Press, Beijing, 1994, pp. 176-179.
14. Zhang F. R., Foreign Medicine-Clinic Biochemistry Branch, 3, 1-5 (1982).
15. Qian Lie Kang is a preparation of pure farina, and contains such ingredients as proteins, polypeptides, carbohydrates, many kinds of vitamins, microelements and other active substances. Its pharmacological effects are as follows: (1) Resembles a female hormone in resisting the effect of a male hormone. (2) Suppresses the hyperplasia of prostate by inhibiting the catalysis of 5 a-reductase on testosterone and then reducing the level of di-hydrogen testosterone (DHT). (3) Regulates strain of leiomyo in urinary system by blocking adrenergic receptor. (4) Effect of anti-inflammation in containing micro metallic elements such as Mn21.